Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-10

AUTHORS

Robin L. Jones, Daniela Katz, Elizabeth T. Loggers, Darin Davidson, Eve T. Rodler, Seth M. Pollack

ABSTRACT

Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of durable clinical benefit with antiangiogenic agents in this disease. A retrospective search of patients treated at three sarcoma referral centers was performed to identify patients with advanced chondrosarcoma treated with antiangiogenic agents. The aim of this study was to evaluate the efficacy and safety of antiangiogenic agents in advanced chondrosarcoma. Ten patients were identified; seven with conventional, one each with clear cell, extraskeletal mesenchymal chondrosarcoma and extraskeletal myxoid chondrosarcoma. The median progression-free survival for patients with conventional and clear cell sarcoma was 22.6 months. Median overall survival has not been met. Antiangiogenic therapy was well tolerated in this series of patients. Our retrospective data suggest that antiangiogenic therapy can provide prolonged clinical benefit in advanced chondrosarcoma patients. Further prospective trials are required to precisely define the role of this class of agent in advanced chondrosarcoma. More... »

PAGES

167

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-017-1030-2

DOI

http://dx.doi.org/10.1007/s12032-017-1030-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091389329

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28852958


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chondrosarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Connective and Soft Tissue", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA", 
            "Sarcoma Unit, Royal Marsden Hospital/Institute of Cancer Research, Fulham Road, SW3 6JJ, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Robin L.", 
        "id": "sg:person.01110361365.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Assaf Harofeh Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413990.6", 
          "name": [
            "Institute of Oncology, Assaf Harofeh Medical Center, Zrifin, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katz", 
        "givenName": "Daniela", 
        "id": "sg:person.014466730563.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014466730563.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA", 
            "Division of Oncology, University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Loggers", 
        "givenName": "Elizabeth T.", 
        "id": "sg:person.01350137274.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350137274.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davidson", 
        "givenName": "Darin", 
        "id": "sg:person.0744134104.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744134104.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, Davis", 
          "id": "https://www.grid.ac/institutes/grid.27860.3b", 
          "name": [
            "Division of Oncology, University of California Davis, Sacramento, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodler", 
        "givenName": "Eve T.", 
        "id": "sg:person.01067057264.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067057264.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA", 
            "Division of Oncology, University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pollack", 
        "givenName": "Seth M.", 
        "id": "sg:person.01317174453.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317174453.94"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ejca.2014.03.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001623134"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1590/s1807-59322011000900015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003019415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.4801", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009392507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt374", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012166665"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-016-2618-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013246309", 
          "https://doi.org/10.1186/s12885-016-2618-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-016-2618-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013246309", 
          "https://doi.org/10.1186/s12885-016-2618-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-0265", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018821214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(13)61719-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026636148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2007-0237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033286438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.1607", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034459975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-7-49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034664812", 
          "https://doi.org/10.1186/1471-2407-7-49"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)60651-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040046880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0046-8177(00)80248-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043073672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/fon.13.68", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044763188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00003086-200204000-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060169157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00003086-200204000-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060169157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00003086-200204000-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060169157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075250669", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-10", 
    "datePublishedReg": "2017-10-01", 
    "description": "Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of durable clinical benefit with antiangiogenic agents in this disease. A retrospective search of patients treated at three sarcoma referral centers was performed to identify patients with advanced chondrosarcoma treated with antiangiogenic agents. The aim of this study was to evaluate the efficacy and safety of antiangiogenic agents in advanced chondrosarcoma. Ten patients were identified; seven with conventional, one each with clear cell, extraskeletal mesenchymal chondrosarcoma and extraskeletal myxoid chondrosarcoma. The median progression-free survival for patients with conventional and clear cell sarcoma was 22.6\u00a0months. Median overall survival has not been met. Antiangiogenic therapy was well tolerated in this series of patients. Our retrospective data suggest that antiangiogenic therapy can provide prolonged clinical benefit in advanced chondrosarcoma patients. Further prospective trials are required to precisely define the role of this class of agent in advanced chondrosarcoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12032-017-1030-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "name": "Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma", 
    "pagination": "167", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "50d655a5c657557d11d4ed0aaf7fb4f285f1c74fa39993a6392a57fbeb3aaf7e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28852958"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9435512"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-017-1030-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091389329"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-017-1030-2", 
      "https://app.dimensions.ai/details/publication/pub.1091389329"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000484.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s12032-017-1030-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1030-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1030-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1030-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1030-2'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      62 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-017-1030-2 schema:about N059592125ad14e37a4cb688ed6ebbcc0
2 N3935aeeec491407b89c30e7e1a29203b
3 N3d92e85cb68f4c598f69e354a03074ca
4 N411690960a144b088ff30bc48ce9fdbc
5 N5c85b97bf65742538ac666afa5f60328
6 N721404f5446546df812cdb28dc17216b
7 N7b40ed2d071842dfa413b32249abe09d
8 N91b911c2e80d44e782beb813b3a5d7e2
9 N931c4ec32f5446c19a3d7e8d1d91f399
10 N9af6d1f2e8124f3a876cf8efbaa063b5
11 Na99d7317a32d4948bdb8d41555fbe7df
12 Naf9ef6561db34e05893be4daba269777
13 Nbf4d1682f2384d8d889b35b30665387b
14 Nd902f3aeef704d8580765a0af4f0ee72
15 Nef08edb6052a461da110ce8ce1ebd21c
16 Nf5435eede0654f578fd43a90442faf0b
17 Nf727e836edc644f8adc9b54eaf5f7bc3
18 Nf9580d64b7eb44a7ab118d0ba8a32d8e
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Nac5c2b067dd242f093569b882897e414
22 schema:citation sg:pub.10.1186/1471-2407-7-49
23 sg:pub.10.1186/s12885-016-2618-1
24 https://app.dimensions.ai/details/publication/pub.1075250669
25 https://doi.org/10.1002/ijc.1607
26 https://doi.org/10.1016/j.ejca.2014.03.013
27 https://doi.org/10.1016/s0046-8177(00)80248-8
28 https://doi.org/10.1016/s0140-6736(12)60651-5
29 https://doi.org/10.1016/s0140-6736(13)61719-5
30 https://doi.org/10.1093/annonc/mdt374
31 https://doi.org/10.1097/00003086-200204000-00011
32 https://doi.org/10.1200/jco.2005.03.4801
33 https://doi.org/10.1590/s1807-59322011000900015
34 https://doi.org/10.1634/theoncologist.2007-0237
35 https://doi.org/10.1634/theoncologist.2010-0265
36 https://doi.org/10.2217/fon.13.68
37 schema:datePublished 2017-10
38 schema:datePublishedReg 2017-10-01
39 schema:description Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of durable clinical benefit with antiangiogenic agents in this disease. A retrospective search of patients treated at three sarcoma referral centers was performed to identify patients with advanced chondrosarcoma treated with antiangiogenic agents. The aim of this study was to evaluate the efficacy and safety of antiangiogenic agents in advanced chondrosarcoma. Ten patients were identified; seven with conventional, one each with clear cell, extraskeletal mesenchymal chondrosarcoma and extraskeletal myxoid chondrosarcoma. The median progression-free survival for patients with conventional and clear cell sarcoma was 22.6 months. Median overall survival has not been met. Antiangiogenic therapy was well tolerated in this series of patients. Our retrospective data suggest that antiangiogenic therapy can provide prolonged clinical benefit in advanced chondrosarcoma patients. Further prospective trials are required to precisely define the role of this class of agent in advanced chondrosarcoma.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf N43525b0ca9f54586a0b914f5cd52a1a4
44 Nced45821c9d44a31a8941eb5022acce9
45 sg:journal.1094524
46 schema:name Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
47 schema:pagination 167
48 schema:productId N451fa3841e9946409f029e30f3957f4c
49 N4e77a12a337640379457c91867a1698c
50 N864371adec81411e9e5b65fe83ea6d08
51 Nc24b4ade05724df8876e14e53e60c1a2
52 Nf74b2bd7c87c455caba377a968c749bf
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091389329
54 https://doi.org/10.1007/s12032-017-1030-2
55 schema:sdDatePublished 2019-04-10T14:02
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N0bc90164fc7541d0b1035ed0c275419e
58 schema:url http://link.springer.com/10.1007/s12032-017-1030-2
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N01bd964272c6443d856f084682e5c503 rdf:first sg:person.0744134104.70
63 rdf:rest N3abaa1daf86a4190943e863e59cf0d82
64 N059592125ad14e37a4cb688ed6ebbcc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Disease-Free Survival
66 rdf:type schema:DefinedTerm
67 N0bc90164fc7541d0b1035ed0c275419e schema:name Springer Nature - SN SciGraph project
68 rdf:type schema:Organization
69 N3935aeeec491407b89c30e7e1a29203b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Retrospective Studies
71 rdf:type schema:DefinedTerm
72 N3abaa1daf86a4190943e863e59cf0d82 rdf:first sg:person.01067057264.26
73 rdf:rest Ne9b2c4a819b04b1ea1d9a0bd56e7da52
74 N3d92e85cb68f4c598f69e354a03074ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Antineoplastic Combined Chemotherapy Protocols
76 rdf:type schema:DefinedTerm
77 N411690960a144b088ff30bc48ce9fdbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Aged
79 rdf:type schema:DefinedTerm
80 N43525b0ca9f54586a0b914f5cd52a1a4 schema:issueNumber 10
81 rdf:type schema:PublicationIssue
82 N451fa3841e9946409f029e30f3957f4c schema:name nlm_unique_id
83 schema:value 9435512
84 rdf:type schema:PropertyValue
85 N4c00bf3395b94cf3a7551268e46a5e2e rdf:first sg:person.014466730563.38
86 rdf:rest N641094c6475e4d4290b368bd9f02c916
87 N4e77a12a337640379457c91867a1698c schema:name doi
88 schema:value 10.1007/s12032-017-1030-2
89 rdf:type schema:PropertyValue
90 N4f9282f0a06a44e7a23013339f83e876 schema:name Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
91 Sarcoma Unit, Royal Marsden Hospital/Institute of Cancer Research, Fulham Road, SW3 6JJ, London, UK
92 rdf:type schema:Organization
93 N5c85b97bf65742538ac666afa5f60328 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Chondrosarcoma
95 rdf:type schema:DefinedTerm
96 N641094c6475e4d4290b368bd9f02c916 rdf:first sg:person.01350137274.50
97 rdf:rest N01bd964272c6443d856f084682e5c503
98 N721404f5446546df812cdb28dc17216b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Humans
100 rdf:type schema:DefinedTerm
101 N7b40ed2d071842dfa413b32249abe09d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Male
103 rdf:type schema:DefinedTerm
104 N864371adec81411e9e5b65fe83ea6d08 schema:name dimensions_id
105 schema:value pub.1091389329
106 rdf:type schema:PropertyValue
107 N91b911c2e80d44e782beb813b3a5d7e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Adult
109 rdf:type schema:DefinedTerm
110 N931c4ec32f5446c19a3d7e8d1d91f399 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Pyrimidines
112 rdf:type schema:DefinedTerm
113 N9af6d1f2e8124f3a876cf8efbaa063b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Female
115 rdf:type schema:DefinedTerm
116 Na99d7317a32d4948bdb8d41555fbe7df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Antibodies, Monoclonal
118 rdf:type schema:DefinedTerm
119 Nac5c2b067dd242f093569b882897e414 rdf:first sg:person.01110361365.31
120 rdf:rest N4c00bf3395b94cf3a7551268e46a5e2e
121 Naf9ef6561db34e05893be4daba269777 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Treatment Outcome
123 rdf:type schema:DefinedTerm
124 Nbf4d1682f2384d8d889b35b30665387b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Middle Aged
126 rdf:type schema:DefinedTerm
127 Nc24b4ade05724df8876e14e53e60c1a2 schema:name readcube_id
128 schema:value 50d655a5c657557d11d4ed0aaf7fb4f285f1c74fa39993a6392a57fbeb3aaf7e
129 rdf:type schema:PropertyValue
130 Nced45821c9d44a31a8941eb5022acce9 schema:volumeNumber 34
131 rdf:type schema:PublicationVolume
132 Nd902f3aeef704d8580765a0af4f0ee72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Sulfonamides
134 rdf:type schema:DefinedTerm
135 Ne9b2c4a819b04b1ea1d9a0bd56e7da52 rdf:first sg:person.01317174453.94
136 rdf:rest rdf:nil
137 Nef08edb6052a461da110ce8ce1ebd21c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Bone Neoplasms
139 rdf:type schema:DefinedTerm
140 Nf5435eede0654f578fd43a90442faf0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Angiogenesis Inhibitors
142 rdf:type schema:DefinedTerm
143 Nf727e836edc644f8adc9b54eaf5f7bc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Neoplasms, Connective and Soft Tissue
145 rdf:type schema:DefinedTerm
146 Nf74b2bd7c87c455caba377a968c749bf schema:name pubmed_id
147 schema:value 28852958
148 rdf:type schema:PropertyValue
149 Nf9580d64b7eb44a7ab118d0ba8a32d8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Lung Neoplasms
151 rdf:type schema:DefinedTerm
152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
153 schema:name Medical and Health Sciences
154 rdf:type schema:DefinedTerm
155 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
156 schema:name Oncology and Carcinogenesis
157 rdf:type schema:DefinedTerm
158 sg:journal.1094524 schema:issn 1357-0560
159 1559-131X
160 schema:name Medical Oncology
161 rdf:type schema:Periodical
162 sg:person.01067057264.26 schema:affiliation https://www.grid.ac/institutes/grid.27860.3b
163 schema:familyName Rodler
164 schema:givenName Eve T.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067057264.26
166 rdf:type schema:Person
167 sg:person.01110361365.31 schema:affiliation N4f9282f0a06a44e7a23013339f83e876
168 schema:familyName Jones
169 schema:givenName Robin L.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31
171 rdf:type schema:Person
172 sg:person.01317174453.94 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
173 schema:familyName Pollack
174 schema:givenName Seth M.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317174453.94
176 rdf:type schema:Person
177 sg:person.01350137274.50 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
178 schema:familyName Loggers
179 schema:givenName Elizabeth T.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350137274.50
181 rdf:type schema:Person
182 sg:person.014466730563.38 schema:affiliation https://www.grid.ac/institutes/grid.413990.6
183 schema:familyName Katz
184 schema:givenName Daniela
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014466730563.38
186 rdf:type schema:Person
187 sg:person.0744134104.70 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
188 schema:familyName Davidson
189 schema:givenName Darin
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744134104.70
191 rdf:type schema:Person
192 sg:pub.10.1186/1471-2407-7-49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034664812
193 https://doi.org/10.1186/1471-2407-7-49
194 rdf:type schema:CreativeWork
195 sg:pub.10.1186/s12885-016-2618-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013246309
196 https://doi.org/10.1186/s12885-016-2618-1
197 rdf:type schema:CreativeWork
198 https://app.dimensions.ai/details/publication/pub.1075250669 schema:CreativeWork
199 https://doi.org/10.1002/ijc.1607 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034459975
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/j.ejca.2014.03.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001623134
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/s0046-8177(00)80248-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043073672
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/s0140-6736(12)60651-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040046880
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/s0140-6736(13)61719-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026636148
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1093/annonc/mdt374 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012166665
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1097/00003086-200204000-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060169157
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1200/jco.2005.03.4801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009392507
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1590/s1807-59322011000900015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003019415
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1634/theoncologist.2007-0237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033286438
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1634/theoncologist.2010-0265 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018821214
220 rdf:type schema:CreativeWork
221 https://doi.org/10.2217/fon.13.68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044763188
222 rdf:type schema:CreativeWork
223 https://www.grid.ac/institutes/grid.27860.3b schema:alternateName University of California, Davis
224 schema:name Division of Oncology, University of California Davis, Sacramento, CA, USA
225 rdf:type schema:Organization
226 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
227 schema:name Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, WA, USA
228 Division of Oncology, University of Washington, Seattle, WA, USA
229 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
230 rdf:type schema:Organization
231 https://www.grid.ac/institutes/grid.413990.6 schema:alternateName Assaf Harofeh Medical Center
232 schema:name Institute of Oncology, Assaf Harofeh Medical Center, Zrifin, Israel
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...